Adalimumab, Serum
Test Mnemonic
ADALIM
CPT Codes
- 83529 - QTY (1)
- 80145 - QTY (1)
Performing Laboratory
Cleveland Clinic Laboratories
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 1 mL | Serum | SST (Gold) | Refrigerated |
Alternate Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 1 mL | Serum | No additive (Red) | Refrigerated |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 0.5 mL |
Stability
| Environmental Condition | Description |
|---|---|
| Ambient | 7 Days |
| Refrigerated | 14 Days |
| Frozen | 60 Days |
Days Performed
Mon, Thu
Turnaround Time
1 - 4 days
Methodology
| Name | Description |
|---|---|
| Enzyme-Linked Immunosorbent Assay (ELISA) |
Special Info
Patients taking a biotin dose greater than 5 mg/day should refrain from taking biotin for at least 24 hours. Clinicians should consider biotin interference as a source of error, when clinically suspicious of the laboratory result.
Clinical Info
Trough free adalimumab level and total (free and bound) anti-drug antibody levels for patients undergoing therapy with adalimumab and -atto. Draw just prior to scheduled dose. In adults with active IBD treated with anti-TNF agents, the AGA suggests reactive therapeutic drug monitoring to guide treatment changes. Reference ranges and high/low indicator flags are provided as general guidelines only. The treating physician must determine appropriate target levels/dosing based on the specific clinical situation.
Clinical Limitation
Adalimumab drug levels greater than 10 ug/mL may result in falsely-decreased adalimumab anti-drug antibody levels.